Asthma was characterized by markedly increased ETP (1508.3 [1342–1680.7] vs. 1255 [1078.6–1454.2] nmol/l thrombin min, p < 0.0001), higher thrombin peak (283.6 [244.3–328.5] vs. 200.5 [154.1–229.6] nmol/l, p < 0.0001), faster rate of thrombin formation (time to peak) (5 [4.67–6] vs. 5.92 [5.17–7.13] min, p < 0.0001), together with higher total amount of prothrombin converted (904.7 [797–1026] vs. 848.1 [739.4–937] nmol/l, p = 0.03), and lower thrombin inactivation capacity (thrombin decay capacity) (0.63 [0.58–0.69] vs. 0.7 (0.6–0.75) min−1, p = 0.0004), as compared with control subjects. The gene discussed is F2; the disease is asthma.